Obesity and metabolic syndrome: Future therapeutics based on novel molecular pathways

Clinica e Investigacion en Arteriosclerosis

Volumn 24, Issue 4, 2012, Pages 204-211

  Gutiérrez Salmeán, Gabriela ^a   Ceballos Reyes, Guillermo ^a   Ramírez Sánchez, Israel ^a  

^a INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

Author keywords

Antiobesity therapies; Flavonoids; Metabolic syndrome; Mitochondrial dysfunction; Obesity

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; SIBUTRAMINE; SIRTUIN 1; TETRAHYDROLIPSTATIN;

DIET THERAPY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; HUMAN; HYPERTENSION; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LOW CARBOHYDRATE DIET; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OXIDATIVE STRESS; PROTEIN DIET; PROTEIN EXPRESSION; SHORT SURVEY; WEIGHT REDUCTION;

EID: 84864301605     PISSN: 02149168     EISSN: 15781879     Source Type: Journal    
DOI: 10.1016/j.arteri.2011.11.002     Document Type: Short Survey

References (101)

1. National Heart, Lung and Blood Institute/National Institute of Diabetes and Digestive and Kidney Diseases. Clinical guidelines on the identification, evaluation and treatment of overweight and obesity in adults: the evidence report. [On line] cited 2011 June [2011 April]. Available at: URL: http://www.nhlbi.nih.gov/guidelines/obesity/index.htm.
2. World Health Organization (WHO). Obesity: preventing and managing the global epidemic. Report of a WHO consultation on obesity. Ginebra; 1999.
3. Loos R.J., Bouchard C. Obesity: is it a genetic disorder?. J Intern Med 2003, 254:401-425.
4. Bell G.C., Walley A.J., Froguel P. The genetics of human obesity. Nat Rev Genet 2005, 6:221-234.
5. O'Rahilly S., Farooqi I.S. Genetics of obesity. Phil Trans R Soc B 2006, 361:1095-1105.
6. Snyder E.E., Walts B., Perusse L., Chagnon Y.C., Weisnagel S.J., Rankinen T., et al. The human obesity gene map: the 2003 update. Obes Res 2004, 12:369-439.
7. Lyon H.N., Hirschhorn J.N. Genetics of common forms of obesity: a brief overview. Am J Clin Nutr 2005, 82(Suppl):215S-217S.
8. Newell A., Zlot A., Silvey K., Arail K. Addressing the obesity epidemic: a genomics perspective. Prev Chronic Dis 2007, 4:1-6.
9. Pi-Sunyer F.X. The obesity epidemic: pathophysiology and consequences of obesity. Obes Res 2002, 10(Suppl 2):97S-104S.
10. Afridi A, Khan A. Prevalence and etiology of obesity: an overview. Pak J Nutr 2204;3:14-25.
11. Luengo-Pérez L.M., Beato-Víbora P. Obesiad y sus complicaciones. Nutr Hosp 2010, 3(Suppl 1):51-61.
12. Ravussin E., Valencia M.E., Esparza J., Bennett P.H., Schulz L.O. Effects of a traditional lifestyle on obesity in Pima Indians. Diabetes 1994, 17:1067-1074.
13. Baier L.J., Hanson R.L. Genetic studies of the etiology of type 2 diabetes in Pima Indians: hunting for the pieces to a complicated puzzle. Diabetes 2004, 53:1181-1186.
14. Esparza J., Fox C., Harper I.T., Bennett P.H., Schulz L.O., Valencia M.E., et al. Daily energy expenditure in Mexican and USA Pima Indians: low physical activity as a possible cause of obesity. Int J Obes Relat Metab Disord 2000, 24:55-59.
15. Schultz L.O., Bennett P.H., Ravussin E., Kidd J.R., Kidd K.K., Esparza J., et al. Effects of a traditional and western environment on prevalence of type 2 diabetes in Pima Indians in Mexico and the U.S. Diabetes Care 2006, 29:1866-1871.
16. Jebb S.A., Rennie K.L., Cole T.J. Prevalence of overweight and obesity among young people in Great Britain. Public Health Nutr 2004, 7:461-465.
17. World Health Organization Obesity and overweight: fact sheet 311. [On line] 2011 February [cited 2011 February]. Available at: URL: http://www.who.int/mediacentre/factsheets/fs311/en/.
18. Organization for Economic Cooperation and Development (OECD). Obesity and the economics of prevention: fit not fat. [On line] 2010 September 23 [cited 2010 October]. Available at: URL: http://www.oecd.org/document/31/.
19. Guh D.P., Zhang W., Bansback N., Amarsi Z., Birmingham C.L., Anis A.H. The incidence of comorbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health 2009, 9:88.
20. Huang P.L. A comprehensive definition for metabolic syndrome. Dis Model Mech 2009, 2:231-237.
21. Grundy S.M. Metabolic syndrome: a multiplex cardiovascular risk factor. J Clin Endocrinol Metabol 2007, 92:399-404.
22. Reaven G.M. Insulin resistance, cardiovascular disease, and the metabolic syndrome: how well do the emperor's clothes fit. Diabetes Care 2004, 27:1011-1012.
23. Shirai K. Obesity as the core of the metabolic syndrome and the management of coronary heart disease. Curr Med Res Opin 2004, 20:295-304.
24. Despres J.P., Lemieux I., Bergenton J., Pibarot P., Mathieu P., Larose E., et al. Abdominal obesity and the metabolic syndrome: a contribution to global cardiometabolic risk. Arterioscler Thromb Vasc Biol 2008, 28:1039-1049.
25. Phillips L.K., Prins J.B. The link between abdominal obesity and the metabolic syndrome. Curr Hypertens Rep 2008, 10:156-164.
26. Despres J.P. Is visceral obesity the cause of the metabolic syndrome. Ann Med 2006, 38:52-63.
27. Despres J.P. Health consequences of visceral adiposity. Ann Med 2001, 33:534-541.
28. Hu G., Qiao Q., Tuomilehto J., Balkau B., Borch-Johnsen K., Pyorala K. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in non-diabetic European men and women. Arch Intern Med 2004, 164:1066-1076. DECODE Study Group.
29. Ruan H., Lodish H.F. Insulin resistance in adipose tissue: direct and indirect effects of tumor necrosis factor-alpha. Cytokine Growth Factor Rev 2003, 14:447-455.
30. Redinger R.N. The pathophysiology of obesity and its clinical manifestations. Gastroenterol Hepatol 2007, 3:856-863.
31. Ritchie S.A., Connell J.M.C. The link between abdominal obesity, metabolic syndrome and cardiovascular disease. Nutr Metabol Cardiovasc Dis 2007, 17:319-326.
32. Kerchaw E.E., Flier J.S. Adipose tissue as en endocrine organ. J Clin Endocrinol Metab 2004, 89:2548-2556.
33. Rasouli N., Kern P.A. Adipocytokines and the metabolic complications of obesity. J Clin Endocrinol Metab 2008, 93:s64-s73.
34. Weisberg S.P., McCann D., Desai M., Rosenbaum M., Leibel R.L., Ferrante A.W. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003, 112:1785-1788.
35. Christiansen T., Richelsen B., Bruun J.M. Monocyte chemoattractant protein-1 is produced in isolated adipocytes: associated with adiposity and reduced after weight loss in morbid obese subjects. Int J Obes 2005, 29:146-150.
36. Bastard J.P., Maachi M., Lagathu C., Kim M.J., Caron M., Vidal H., et al. Recent advances in the relationship between obesity: inflammation, and insulin resistance. Eur Cytokine Netw 2006, 17:4-12.
37. Boden G., Lebed B., Schatz M., Homko C., Lemieux S. Effects of acute changes in plasma free fatty acids on intramyocellular fat content and insulin resistance in healthy subjects. Diabetes 2001, 50:1612-1617.
38. Itani S.I., Ruderman N.B., Schmieder F., Boden G. Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IkappaB-alpha. Diabetes 2002, 51:2005-2011.
39. Unger R.H. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Diabetes 1995, 44:863-870.
40. Duvnjak L., Duvnjak M. The metabolic syndrome: an ongoing story. J Physiol Pharmacol 2009, 60(Suppl 7):19-24.
41. Reaven J.M. Insulin resistance and its consequences. Diabetes mellitus: a fundamental and clinical text 2004, Lippincott, Williams and Wilkins, USA. D. LeRoith, S.I. Taylor, J.M. Olefsky (Eds.).
42. Montagnani M., Quon M.J. Insulin action in vascular endothelium: potential mechanisms linking insulin resistance with hypertension. Diabetes Obes Metab 2000, 2:285-292.
43. Kim J.A., Montagnani M., Koh K.K., Quon M.J. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 2006, 113:1888-1904.
44. Atochin D.N., Wang A., Liu V.W., Critchlow J.D., Dantas A.P., Looft-Wilson R., et al. The phosphorylation state of eNOS modulates vascular reactivity and outcome of cerebral ischemia. J Clin Invest 2007, 117:1961-1967.
45. Flakoll P.J., Jensen M.D., Cherrington A.D. Physiological action of insulin. Diabetes mellitus: a fundamental and clinical text 2004, Lippincott, Williams and Wilkins, EUA. D. LeRoith, S.I. Taylor, J.M. Olefasky (Eds.).
46. Huang P.L. Unraveling the links between diabetes, obesity and cardiovascular disease. Circ Res 2005, 96:1129-1131.
47. Morrow J. Is oxidative stress a connection between obesity and atherosclerosis. Arterioscler Tromb Vasc Boil 2003, 23:368-370.
48. Fernández-Sánchez A., Madrigal-Santillán F., Bautista M., Esquivel-Soto J., Morales-González A., Esquivel-Chirino C., et al. Inflammation, oxidative stress and obesity. Int J Mol Sci 2011, 12:3117-3132.
49. Semenkovich C.F. Insulin resistance and atherosclerosis. J Clin Invest 2006, 116:1813-1822.
50. Miccoli R., Bianchi C., Penno G., Del Prato S. Insulin resistance and lipid disorders: dysregulation of lipid metabolism. Future Lipidol 2008, 3:651-664.
51. Howard B.V. Insulin resistance and lipid metabolism. Am J Cardiol 1999, 84:28J-32J.
52. Raz I., Eldor R., Cernea S., Shafrir E. Diabetes: insulin resistance and derangements in lipid metabolism. Diabetes Metab Res Rev 2005, 21:3-14.
53. Bhopal R.S., Rafnsson S.B. Could mitochondrial efficiency explain the susceptibility to adiposity, metabolic syndrome, diabetes and cardiovascular diseases in South Asian populations. Int J Epidemiol 2009, 38:1072-1081.
54. Bournat J.C., Brown C.W. Mitochondrial dysfunction in obesity. Curr Opin Endocrinol Diabetes Obes 2010, 17:446-452.
55. Rolo A.P., Gomez A.P., Palmeira C.M. Regulation of mitochondrial biogenesis in metabolic syndrome. Curr Drug Targets 2011, 12:872-878.
56. Lagouge M., Argmann C., Gerhart-Hines Z., Meziane H., Lerin C., Daussin F., et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1α. Cell 2006, 127:1109-1122.
57. Kota B.P., Huang T.H., Roufogalis B.D. An overview on biological mechanisms of PPARs. Pharmacol Res 2005, 51:85-94.
58. Yessoufou A., Wahli W. Multifaceted roles or peroxisome proliferator-activated receptors (PPARs) at the cellular and whole organism levels. Swiss Med Wkly 2010, 140:E1-E10.
59. Desvergne B., Wahli W. Peroxisome proliferator activated receptors: nuclear control of metabolism. Endocrinol Rev 1999, 20:649-688.
60. Tontonoz P., Hu E., Graves R.A., Budavari A.I., Spiegelman B.M. mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev 1994, 8:1224-1234.
61. Risérus U., Sprecher D., Johnson T., Olson E., Hirschberg S., Liu A., et al. Activation of PPARα promotes reversal of multiple metabolic abnormalities: reduces oxidative stress and increases fatty acid oxidation in moderately obese men. Diabetes 2008, 57:332-339.
62. Barish G.D., Narkar V.A., Evans R.M. PPAR delta: a dagger in the heart of metabolic syndrome. J Clin Invest 2006, 116:590-597.
63. Farmer S.R. Molecular determinants of brown adipocyte formation and function. Genes Dev 2008, 22:1397-1409.
64. Wilson-Fritch L., Burkart A., Bell G., Mendelson K., Leszyk J., Nicoloro S., et al. Mitochondrial biogenesis and remodeling during adipogenesis and in response to the insulin sensitizer rosiglitazone. Mol Cell Biol 2003, 23:1085-1094.
65. Wilson-Fritch L., Nicoloro S., Chouinard M., Lazar M.A., Chui P.C., Leszyk J., et al. Mitochondrial remodeling in adipose tissue associated with obesity and treatment with rosiglitazone. J Clin Invest 2004, 114:1281-1289.
66. Rodríguez-Calvo R., Serrano L., Coll T., Moullan N., Sánchez R.M., Merlos M., et al. Activation of the peroxisome proliferator-activated receptor β/δ inhibits lipopolisacharide-induced cytokine production in adipocytes. Diabetes 2008, 57:2149-2157.
67. Coll T., Barrosso E., Álvarez-Guardia D., Serrano L., Salvadó L., Merlos M., et al. The role of peroxisome proliferator-activated receptors β/δ on the inflammatory basis of metabolic disease. PPAR Res 2010, 10.1155/2010/368467.
68. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003, 3:23-25.
69. Straus D.S., Glass C.K. Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. Trends Immunol 2007, 28:551-558.
70. Fuentes L., Rószer T., Ricote M. Inflammatory mediators and insulin resistance in obesity: role of nuclear receptor signaling in macrophages. Mediat Inflamm 2010, 10.1155/2010/219583.
71. Madej A., Okopien B., Kowalski J., Zielinski M., Wysocki J., Szygula B., et al. Effects of fenofibrate on plasma cytokine concentrations in patients with atherosclerosis and hyperlipoproteinemia IIb. Int J Clin Pharmacol Ther 1998, 36:345-349.
72. Bassaganya J., Guri A.J., Hontecillas R. Treatment of obesity related complications with novel classes of naturally occurring PPAR agonists. J Obes 2011, 10.1155/2011/897894.
73. Liang H., Ward W.F. PGC-1α: a key regulator of energy metabolism. Adv Physiol Educ 2006, 30:145-151.
74. Finck B.N., Kelly D.P. PGC-1 coactivators: inducible regulators of energy metabolism in health and disease. J Clin Invest 2006, 116:615-622.
75. Puigserver P., Wu Z., Park C.W., Graves R., Wright M., Spiegelman B.M. A cold-inducible coactivator of nuclear receptors linked to adaptative thermogenesis. Cell 1998, 92:829-839.
76. Scarpulla R.C. Nuclear activators and coactivators in mammalian mitochondrial biogenesis. Biochim Biophys Acta 2002, 1576:1-14.
77. Scarpulla R.C. Transcriptional activators and coactivators in the nuclear control of mitochondrial function in mammal cells. Gene 2002, 286:81-89.
78. Russel A.P., Feilchenfeldt J., Schreiber S., Praz M., Crettenand A., Gobelet C., et al. Endurance in training humans lead to fiber type-specific increases in levels of PGC-1alpha and PPARalpha in skeletal muscle. Diabetes 2003, 52:2874-2881.
79. Liang H., Ward W.F. PGC-1α: a key regulator of energy metabolism. Adv Physiol Edu 2006, 30:145-151.
80. Nagamoto F., Gu N., Fujino H., Takeda I., Tsuda K., Ishihara A. Skeletal muscle characteristics of rats with obesity, diabetes, hypertension and hyperlipidemia. J Atheroscler Thromb 2009, 16:576-585.
81. Fernández-Marcos P.J., Auwerx J. Regulation of PGC-1α: a nodal regulator of mitochondrial biogenesis. Am J Clin Nutr 2011, 93:884S-890S.
82. Yang T., Sauve A.A. NAD metabolism and sirtuins: metabolic regulation of protein deacetylase in stress and toxicity. AAPS J 2006, E632-E643.
83. Chaudhary N., Pfluger P.T. Metabolic benefits from Sirt1 and Sirt1 activators. Curr Opin Clin Nutr Metabol Care 2009, 12:431-437.
84. Lagouge M., Argmann C., Gerhart-Hines Z., Meziane H., Lerin C., Daussin F., et al. Resveratrol improves mitochondrial function and protects against metabolic diseases by activating SIRT1 and PGC-1alpha. Cell 2006, 127:1109-1122.
85. Gerhart-Hines Z., Rodgers J.T., Bare O., Lerin C., Kim S.H., Mostoslavsky R., et al. Metabolic control of muscle mitochondrial function and fatty acid oxidation through SIRT1/PGC-1alpha. EMBO J 2007, 26:1913-1923.
86. Rodgers J.T., Lerin C., Haas W., Gygi S.P., Spiegelman B.M., Puigserver P. Nutrient control of glucose homeostasis through a complex of PGC-1 alpha and SIRT1. Nature 2005, 434:113-118.
87. Picard F., Kurtev M., Chung N., Topark-Ngarm A., Senawong T., Machado De Oliveira R., et al. Sirt1 promotes fat mobilization in white adipocyes by repressing PPAR-gamma. Nature 2004, 429:771-776.
88. Zillikens M.C., van Meurs J.B.J., Rivadeneira F., Amin N., Hofman A., Oostra B.A., et al. SIRT1 genetic variation in related to BMI and risk of obesity. Diabetes 2009, 58:2828-2834.
89. Campos B.S.I., Hernández M.L. Tratamiento de la obesidad. Síndrome metabólico y enfermedad cardiovascular 2009, Intersistemas Editores, México. 3a ed. A. González, F.J. Lavalle, J.J. Ríos (Eds.).
90. Saper R., Eisenberg D., Russell S.P. Common dietary supplements for weight loss. Am Fam Physician 2004, 70:1731-1738.
91. Mutch D.M., Wahli W., Williamson G. Nutrigenomics and nutrigenetics: the emerging faces of nutrition. FASEB J 2005, 160:2-16.
92. Baur J.A., Pearson K.J., Price N.L., et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006, 444:337-342.
93. Alcain F.J., Villalba J.M. Sirtuin activators. Expert Opin Ther Pat 2009, 19:403-414.
94. Kaeberlein M., McDonagh T., Heltweg B., Hixon J., Westman E.A., Caldwell S.D., et al. Substrate-specific activation of sirtuins by resveratrol. J Biol Chem 2005, 280:17038-17045.
95. Beher D., Wu J., Cumine S., Kim K.W., Lu S.C., Atangan L., et al. Resveratrol is not a direct activator of SIRT1 enzyme activity. Chem Biol Drug Des 2009, 74:619-624.
96. Feige J.N., Lagouge M., Canto C., Strehle A., Houten S.M., Milne J.C., et al. Specific SIRT1 activation mimics low energy levels and protects against diet-induced metabolic disorders by enhancing fat oxidation. Cell Metab 2008, 8:347-358.
97. Orggard A., Jensen L. The effects of soy isoflavones on obesity. Exp Biol Med 2008, 233:1066-1080.
98. Mulvihill E.E., Allister E.M., Sutherland B.G., Telford D.E., Sawyez C.G., Edwards J.Y., et al. Naringenin prevents dyslipidemia, apolipoprotein B overproduction, and hyperinsulinemia in LDL receptornull mice with diet-induced insulin resistance. Diabetes 2009, 58:2198-2210.
99. Honda S., Tominaga Y., Yokota S. Licorice flavonoids. Nutrigenomics and proteomics in health and disease 2009, 299-309. Wiley-Blackwell, EUA. Y. Mine, K. Miyashita, F. Shahidi (Eds.).
100. Kamiyosama H., Honda K., Tominaga Y., Yokota S., Hasegawa S. Investigation of the anti-obesity action of licorice flavonoid oil in diet-induced obese rats. Biosci Biotechnol Biochem 2008, 72:3225-3231.
101. Xia X., Weng J. Targeting metabolic syndrome: candidate natural agents. J Diabetes 2010, 2:243-249.